For those using drugs to treat infants and children, the integration of developmental
pharmacology is crucial to appropriate clinical practice. Changes in metabolic capacity …

In children, the therapeutic benefits and potential risks associated with drug treatment may
be different from those in adults and will depend on the exposure, receptor sensitivity and …

Midazolam is a benzodiazepine with rapid onset of action and short duration of effect. In
healthy neonates the half-life (t 1/2) and the clearance (Cl) are 3.3-fold longer and 3.7-fold …

Introduction Most of the drugs on the market are originally developed for adults and dosage
selection is based on an optimal balance between clinical efficacy and safety. The aphorism …

Seizures are common in neonates with moderate and severe hypoxic ischemic
encephalopathy (HIE) and are associated with worse outcomes, independent of HIE …

Mycophenolate mofetil (MMF) is widely used for maintenance immunosuppressive therapy
in pediatric renal and heart transplant recipients. Children undergo developmental changes …

Cancer is the leading cause of death in American children older than 1 year of age. Major
developments in drugs such as thiopurines and optimization in clinical trial protocols for …

Although midazolam is a frequently used sedative in neonatal intensive care units, its use in
preterm neonates has been off‐label. Recently, a new dosing advice for midazolam for …

A paucity of data exists on the disposition and effect of drugs in young children. This
information gap can be reduced by elucidating developmental principles of absorption …

Purpose Since many drug targets and metabolizing enzymes are developmentally
regulated, we investigated a potential comparable regulation of inosine 5'-monophosphate …